First patients to receive 'Living Drug' in fight against tough leukemia
Disease control
Recruiting now
This is the first-ever study in people of an experimental treatment called CER-1236 for acute myeloid leukemia (AML) that has come back or is resistant to other treatments. Doctors will test the safety and early effectiveness of this therapy, which uses a patient's own immune cel…
Phase: PHASE1 • Sponsor: CERo Therapeutics Holdings, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC